Andre Gilbert
Urology · Findlay, OHNPI 1639110885
Payments from drug & device makers
Across 48 payments — averaging $81.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$1K
- Boston Scientific$1K
- Verathon Inc.$400
- Astellas Pharma US Inc$180
- Lumenis, Inc$165
- ARS Pharmaceuticals Operations, Inc.$103
- plus $647 from 16 others
What the payments were for
- Consulting fees$40010%
- Travel & lodging$1,82447%
- Food & beverage$1,54140%
- Education$1243%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 12 | $1,284 |
| Boston Scientific | 8 | $1,110 |
| Verathon Inc. | 1 | $400 |
| Astellas Pharma US Inc | 5 | $180 |
| Lumenis, Inc | 2 | $165 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $103 |
| Dexcom, Inc. | 1 | $95 |
| Coloplast | 1 | $86 |
| Bard Access Systems, Inc. | 3 | $78 |
| Richard Wolf Medical Instruments Corp. | 1 | $74 |
| AstraZeneca | 1 | $48 |
| Johnson & Johnson | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| AbbVie | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Myovant Sciences Inc. | 1 | $24 |
| Endo USA, Inc. | 1 | $23 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Laborie Medical Technologies Corp. | 1 | $17 |
| Urogen Pharma, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$1,085
- GENERAL BPH$823
- NPD Clinical Study$400
- GENERAL KIDNEY STONE DISEASE$143
- NEFFY$103
How this compares
$3,888 in reported general payments places this provider in the 55th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 34 | $287 |
| Finasteride | 16 | $208 |
| Cephalexin | 16 | $42 |
Paid to pharmacies, not to this prescriber.
Other urology in Findlay
- Marc PliskinCincinnati$20.8M
- Lawrence GervasiMiddleburg Heights$4.7M
- Martin FritzhandCincinnati$4.6M
- Kamal PoharCincinnati$3.4M
- Eric SingerColumbus$2.1M
- Benjamin MartinGahanna$1.1M
- Howard GoldmanCleveland$747K
- Jihad KaoukCleveland$696K
- Raymond RackleyCleveland$695K
- Sandip VasavadaCleveland$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.